Paragon Bioservices: JPMorgan Supports Catalent Acquisition of Paragon Bioservices

Catalent, a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, will acquire Paragon Bioservices for $1.2 billion.